U.S. markets closed

Constellation Pharmaceuticals, Inc. (CNST)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.44+1.38 (+7.61%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • Hedge Funds Are Betting On Constellation Pharmaceuticals, Inc. (CNST)
    Insider Monkey

    Hedge Funds Are Betting On Constellation Pharmaceuticals, Inc. (CNST)

    We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

  • GlobeNewswire

    Constellation Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

    CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in upcoming virtual investor conferences.  Jigar Raythatha, CEO, will present at: * The H.C. Wainwright Global Investment Conference at 1:00 PM EDT on September 14 * The Cantor Global Healthcare Conference at 1:20 PM EDT on September 17 Live audio webcasts of Mr. Raythatha’s presentations and archives for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events.  The audio webcast replays will be available for 30 days following the live presentation.About Constellation PharmaceuticalsConstellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.ContactKia Khaleghpour, Ph.D. Vice President, Investor Relations and Communications Constellation Pharmaceuticals +1 617-844-6859 kia.khaleghpour@constellationpharma.comRonald Aldridge Investor Relations Constellation Pharmaceuticals +1 617-714-0539 ron.aldridge@constellationpharma.comLauren Arnold Media Relations MacDougall Biomedical Communications +1 781-235-3060 larnold@macbiocom.com

  • Benzinga

    Benzinga's Top Upgrades, Downgrades For September 3, 2020

    Upgrades * For AGCO Corp (NYSE: AGCO), B of A Securities upgraded the previous rating of Neutral to the current rating Buy. AGCO earned $1.11 in the second quarter, compared to $1.82 in the year-ago quarter. The current stock performance of AGCO shows a 52-week-high of $81.39 and a 52-week-low of $35.33. Moreover, at the end of the last trading period, the closing price was at $73.86. * For JPMorgan Chase & Co (NYSE: JPM), Deutsche Bank upgraded the previous rating of Hold to the current rating Buy. For the second quarter, JPMorgan Chase had an EPS of $1.38, compared to year-ago quarter EPS of $2.59. At the moment, the stock has a 52-week-high of $141.10 and a 52-week-low of $76.91. JPMorgan Chase closed at $101.61 at the end of the last trading period. * According to Deutsche Bank, the prior rating for Bank of America Corp (NYSE: BAC) was changed from Hold to Buy. Bank of America earned $0.37 in the second quarter, compared to $0.74 in the year-ago quarter. The stock has a 52-week-high of $35.72 and a 52-week-low of $17.95. At the end of the last trading period, Bank of America closed at $26.02. * According to Morgan Stanley, the prior rating for Eli Lilly and Co (NYSE: LLY) was changed from Equal-Weight to Overweight. Eli Lilly earned $1.89 in the second quarter, compared to $1.50 in the year-ago quarter. At the moment, the stock has a 52-week-high of $170.75 and a 52-week-low of $101.36. Eli Lilly closed at $149.56 at the end of the last trading period. * For FirstCash Inc (NASDAQ: FCFS), Credit Suisse upgraded the previous rating of Neutral to the current rating Outperform. In the second quarter, FirstCash showed an EPS of $0.62, compared to $0.82 from the year-ago quarter. The stock has a 52-week-high of $101.91 and a 52-week-low of $55.44. At the end of the last trading period, FirstCash closed at $60.81. * For FedEx Corp (NYSE: FDX), Berenberg upgraded the previous rating of Hold to the current rating Buy. FedEx earned $2.53 in the fourth quarter, compared to $5.01 in the year-ago quarter. The stock has a 52-week-high of $229.00 and a 52-week-low of $88.69. At the end of the last trading period, FedEx closed at $227.92. * RBC Capital upgraded the previous rating for FirstEnergy Corp (NYSE: FE) from Sector Perform to Outperform. For the second quarter, FirstEnergy had an EPS of $0.57, compared to year-ago quarter EPS of $0.61. The current stock performance of FirstEnergy shows a 52-week-high of $52.52 and a 52-week-low of $22.85. Moreover, at the end of the last trading period, the closing price was at $29.14. * According to KeyBanc, the prior rating for Whiting Petroleum Corp (NYSE: WLL) was changed from Sector Weight to Overweight. For the second quarter, Whiting Petroleum had an EPS of $6.28, compared to year-ago quarter EPS of $0.28. The stock has a 52-week-high of $28.00 and a 52-week-low of $0.25. At the end of the last trading period, Whiting Petroleum closed at $19.46. Downgrades * According to Berenberg, the prior rating for Nomad Foods Ltd (NYSE: NOMD) was changed from Buy to Hold. In the second quarter, Nomad Foods showed an EPS of $0.37, compared to $0.30 from the year-ago quarter. The current stock performance of Nomad Foods shows a 52-week-high of $25.24 and a 52-week-low of $14.08. Moreover, at the end of the last trading period, the closing price was at $24.84. * According to Kepler Cheuvreux, the prior rating for Autoliv Inc (NYSE: ALV) was changed from Buy to Hold. Autoliv earned $1.40 in the second quarter, compared to $1.38 in the year-ago quarter. At the moment, the stock has a 52-week-high of $87.01 and a 52-week-low of $38.16. Autoliv closed at $79.82 at the end of the last trading period. * For Fastenal Co (NASDAQ: FAST), Wells Fargo downgraded the previous rating of Overweight to the current rating Equal-Weight. For the second quarter, Fastenal had an EPS of $0.42, compared to year-ago quarter EPS of $0.36. The current stock performance of Fastenal shows a 52-week-high of $49.86 and a 52-week-low of $26.71. Moreover, at the end of the last trading period, the closing price was at $49.67. * Berenberg downgraded the previous rating for United Parcel Service Inc (NYSE: UPS) from Hold to Sell. In the second quarter, United Parcel Service showed an EPS of $2.13, compared to $1.96 from the year-ago quarter. At the moment, the stock has a 52-week-high of $166.20 and a 52-week-low of $82.00. United Parcel Service closed at $165.89 at the end of the last trading period. Initiations * Brookline Capital initiated coverage on Constellation Pharmaceuticals Inc (NASDAQ: CNST) with a Buy rating. The price target for Constellation is set to $33.00. For the second quarter, Constellation had an EPS of $0.70, compared to year-ago quarter EPS of $0.80. The current stock performance of Constellation shows a 52-week-high of $59.49 and a 52-week-low of $6.01. Moreover, at the end of the last trading period, the closing price was at $21.18. * With a current rating of Neutral, Credit Suisse initiated coverage on The Hanover Insurance Group Inc (NYSE: THG). The price target seems to have been set at $117.00 for Hanover Insurance Gr. In the second quarter, Hanover Insurance Gr showed an EPS of $1.63, compared to $1.88 from the year-ago quarter. The current stock performance of Hanover Insurance Gr shows a 52-week-high of $144.71 and a 52-week-low of $75.11. Moreover, at the end of the last trading period, the closing price was at $102.40. * Cowen & Co. initiated coverage on Alphatec Holdings Inc (NASDAQ: ATEC) with an Outperform rating. The price target for Alphatec Holdings is set to $12.00. Alphatec Holdings earned $0.25 in the second quarter, compared to $0.26 in the year-ago quarter. At the moment, the stock has a 52-week-high of $7.93 and a 52-week-low of $2.19. Alphatec Holdings closed at $6.09 at the end of the last trading period. * With a current rating of Outperform, Oppenheimer initiated coverage on Workhorse Group Inc (NASDAQ: WKHS). The price target seems to have been set at $23.00 for Workhorse Group. For the second quarter, Workhorse Group had an EPS of $1.76, compared to year-ago quarter EPS of $0.09. At the moment, the stock has a 52-week-high of $22.90 and a 52-week-low of $1.31. Workhorse Group closed at $18.95 at the end of the last trading period. * With a current rating of Buy, Needham initiated coverage on Magnite Inc (NASDAQ: MGNI). The price target seems to have been set at $10.00 for Magnite. In the second quarter, Magnite earned $0.10. The current stock performance of Magnite shows a 52-week-high of $8.29 and a 52-week-low of $5.58. Moreover, at the end of the last trading period, the closing price was at $7.55. * With a current rating of Outperform, Baird initiated coverage on Beyond Meat Inc (NASDAQ: BYND). The price target seems to have been set at $160.00 for Beyond Meat. For the second quarter, Beyond Meat had an EPS of $0.02, compared to year-ago quarter EPS of $0.06. The stock has a 52-week-high of $172.29 and a 52-week-low of $48.18. At the end of the last trading period, Beyond Meat closed at $129.70.See more from Benzinga * Understanding Cisco Systems's Unusual Options Activity * Unusual Options Activity Insight: NIO * Analyzing Nokia's Unusual Options Activity(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.